AU2013203153B2 - Treatment of cancer with TOR kinase inhibitors - Google Patents

Treatment of cancer with TOR kinase inhibitors Download PDF

Info

Publication number
AU2013203153B2
AU2013203153B2 AU2013203153A AU2013203153A AU2013203153B2 AU 2013203153 B2 AU2013203153 B2 AU 2013203153B2 AU 2013203153 A AU2013203153 A AU 2013203153A AU 2013203153 A AU2013203153 A AU 2013203153A AU 2013203153 B2 AU2013203153 B2 AU 2013203153B2
Authority
AU
Australia
Prior art keywords
substituted
pyrazin
unsubstituted
tor kinase
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013203153A
Other languages
English (en)
Other versions
AU2013203153A1 (en
Inventor
Kristen Mae Hege
Heather Raymon
Lilly Loraine WONG
Shuichan Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signal Pharmaceuticals LLC
Original Assignee
Signal Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharmaceuticals LLC filed Critical Signal Pharmaceuticals LLC
Publication of AU2013203153A1 publication Critical patent/AU2013203153A1/en
Priority to AU2015213400A priority Critical patent/AU2015213400B2/en
Application granted granted Critical
Publication of AU2013203153B2 publication Critical patent/AU2013203153B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013203153A 2012-03-15 2013-03-14 Treatment of cancer with TOR kinase inhibitors Ceased AU2013203153B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2015213400A AU2015213400B2 (en) 2012-03-15 2015-08-14 Treatment of cancer with TOR kinase inhibitors

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261611361P 2012-03-15 2012-03-15
US61/611,361 2012-03-15
US201261715323P 2012-10-18 2012-10-18
US61/715,323 2012-10-18
PCT/US2013/031206 WO2013138557A1 (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015213400A Division AU2015213400B2 (en) 2012-03-15 2015-08-14 Treatment of cancer with TOR kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2013203153A1 AU2013203153A1 (en) 2013-10-03
AU2013203153B2 true AU2013203153B2 (en) 2015-09-03

Family

ID=48014336

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013203153A Ceased AU2013203153B2 (en) 2012-03-15 2013-03-14 Treatment of cancer with TOR kinase inhibitors

Country Status (21)

Country Link
US (1) US20130245026A1 (enExample)
EP (1) EP2825170B1 (enExample)
JP (3) JP2015510891A (enExample)
KR (3) KR20210071101A (enExample)
CN (2) CN108992446A (enExample)
AU (1) AU2013203153B2 (enExample)
BR (1) BR112014022703A2 (enExample)
CA (1) CA2866872A1 (enExample)
EA (1) EA028414B1 (enExample)
ES (1) ES2677874T3 (enExample)
IL (1) IL234602B (enExample)
MX (1) MX360878B (enExample)
MY (1) MY174022A (enExample)
NI (1) NI201400111A (enExample)
NZ (1) NZ628416A (enExample)
PH (1) PH12014502029A1 (enExample)
SG (1) SG11201405707XA (enExample)
TW (1) TWI583385B (enExample)
UA (1) UA114315C2 (enExample)
WO (1) WO2013138557A1 (enExample)
ZA (1) ZA201406706B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2677874T3 (es) * 2012-03-15 2018-08-07 Signal Pharmaceuticals, Llc Tratamiento del cáncer con inhibidores de la cinasa TOR
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EP2945636B1 (en) 2013-01-16 2017-06-28 Signal Pharmaceuticals, LLC Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
KR102242505B1 (ko) * 2013-04-17 2021-04-20 시그날 파마소티칼 엘엘씨 암 치료용 tor 키나제 억제제 및 시티딘 유사체를 포함하는 병용 요법
AU2014254057A1 (en) 2013-04-17 2015-11-05 Signal Pharmaceuticals, Llc Combination therapy comprising a TOR kinase inhibitor and N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
JP2016522177A (ja) * 2013-04-17 2016-07-28 シグナル ファーマシューティカルズ,エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
SG11201508527VA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
NZ629411A (en) 2013-04-17 2017-06-30 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
ES2944478T3 (es) 2013-04-17 2023-06-21 Signal Pharm Llc 1-etil-7-(2-metil-6-(1H-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino[2,3-b]pirazin-2(1H)-ona para tratar el glioblastoma multiforme
MX368286B (es) 2013-04-17 2019-09-27 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
BR112015026257B1 (pt) 2013-04-17 2022-12-20 Signal Pharmaceuticals, Llc Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
JP6401250B2 (ja) 2013-05-29 2018-10-10 シグナル ファーマシューティカルズ,エルエルシー 7−(6−(2−ヒドロキシプロパン−2−イル)ピリジン−3−イル)−1−((trans)−4−メトキシシクロヘキシル)−3,4−ジヒドロピラジノ[2,3−b]ピラジン−2(1H)−オン、その固体形態の医薬組成物、及びその使用方法
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
US9737535B2 (en) 2014-04-16 2017-08-22 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
AU2015289929A1 (en) 2014-07-14 2017-03-02 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008051493A2 (en) * 2006-10-19 2008-05-02 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
WO2010022243A1 (en) * 2008-08-20 2010-02-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemoprevention of head and neck squamous cell carcinomas
WO2010062571A1 (en) * 2008-10-27 2010-06-03 Signal Pharmaceuticals, Llc Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/p13k/akt pathway

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2383370T3 (es) 2006-10-19 2012-06-20 Signal Pharmaceuticals Llc Compuestos de heteroarilo, sus composiciones y uso de los mismos como inhibidores de proteína quinasa
JP2013508456A (ja) 2009-10-26 2013-03-07 シグナル ファーマシューティカルズ, エルエルシー ヘテロアリール化合物の合成方法および精製方法
US20120028972A1 (en) * 2010-07-30 2012-02-02 Lilly Wong Biomarker assays for detecting or measuring inhibition of tor kinase activity
ES2677874T3 (es) * 2012-03-15 2018-08-07 Signal Pharmaceuticals, Llc Tratamiento del cáncer con inhibidores de la cinasa TOR

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008051493A2 (en) * 2006-10-19 2008-05-02 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
WO2010022243A1 (en) * 2008-08-20 2010-02-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemoprevention of head and neck squamous cell carcinomas
WO2010062571A1 (en) * 2008-10-27 2010-06-03 Signal Pharmaceuticals, Llc Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/p13k/akt pathway

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AMORNPHIMOLTHAM P, et al. 'A Retroinhibition Approach Reveals a Tumour Cell-Autonomous Response to Rapamycin in Head and Neck Cancer,' Cancer Res, (2008) Vol 68, pp 1144-1153. *
BERK L, et al. Cancer Chemother Pharmacol, (2012) Vol 69, pp 1369-1377. *
EKSHYYAN O, et al. Head Neck, (2010) Vol 32, pp 1619-1628. *

Also Published As

Publication number Publication date
US20130245026A1 (en) 2013-09-19
JP2019108368A (ja) 2019-07-04
IL234602A0 (en) 2014-11-30
EP2825170A1 (en) 2015-01-21
KR102122617B1 (ko) 2020-06-12
IL234602B (en) 2020-05-31
UA114315C2 (uk) 2017-05-25
KR20200070416A (ko) 2020-06-17
HK1201750A1 (en) 2015-09-11
CN108992446A (zh) 2018-12-14
CN104519885A (zh) 2015-04-15
KR20140138927A (ko) 2014-12-04
NI201400111A (es) 2015-01-15
TWI583385B (zh) 2017-05-21
JP2015510891A (ja) 2015-04-13
AU2013203153A1 (en) 2013-10-03
KR20210071101A (ko) 2021-06-15
MY174022A (en) 2020-03-04
BR112014022703A2 (pt) 2021-05-04
WO2013138557A1 (en) 2013-09-19
PH12014502029B1 (en) 2014-11-24
TW201343168A (zh) 2013-11-01
CA2866872A1 (en) 2013-09-19
EA201491699A1 (ru) 2015-02-27
EA028414B1 (ru) 2017-11-30
SG11201405707XA (en) 2014-10-30
ES2677874T3 (es) 2018-08-07
JP2021102637A (ja) 2021-07-15
PH12014502029A1 (en) 2014-11-24
MX2014011077A (es) 2014-10-14
MX360878B (es) 2018-11-21
EP2825170B1 (en) 2018-05-09
ZA201406706B (en) 2016-05-25
NZ628416A (en) 2016-04-29

Similar Documents

Publication Publication Date Title
AU2013203153B2 (en) Treatment of cancer with TOR kinase inhibitors
US20230338370A1 (en) Treatment of Cancer with TOR Kinase Inhibitors
AU2013203156C1 (en) Treatment of cancer with TOR kinase inhibitors
AU2013202992B2 (en) Treatment of cancer with TOR kinase inhibitors
AU2015213400B2 (en) Treatment of cancer with TOR kinase inhibitors
AU2015201138B2 (en) Treatment of cancer with TOR kinase inhibitors
HK1201750B (en) Treatment of cancer with tor kinase inhibitors
HK1201753B (en) Treatment of cancer with tor kinase inhibitors
HK1202247B (en) Treatment of cancer with tor kinase inhibitors
HK1201755B (en) Treatment of cancer with tor kinase inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired